Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 monthsAlberto F. Sobrero, Eric Van Cutsem, Salvatore Siena et al.|Annals of Oncology|2015Cited by 0